Roche announced positive five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo (ranibizumab injection) for the treatment of people with neovascular or ‘wet’ age-related macular degeneration (nAMD).

The data show that Susvimo's durability and efficacy were sustained over five years, with about 95% of people receiving treatment every six months needing no additional treatment between refills. The results were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California.

“These results reinforce Susvimo’s ability to maintain vision and retinal dryness over a long period for people with nAMD, the leading cause of vision loss in people over 60,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “The data support Susvimo as an effective alternative to frequent eye injections.”

John Kitchens, M.D., Retina Associates of Kentucky, who presented the data, said: “In real-world practice, people with nAMD often have suboptimal outcomes due to the burden of frequent injections. Continuous delivery with Susvimo may help maintain vision for longer compared to traditional intravitreal (IVT) injections.”

Susvimo delivers a customised formulation of ranibizumab via the Port Delivery Platform—a refillable eye implant inserted in a one-time outpatient procedure. Unlike monthly injections, it provides continuous drug delivery directly into the eye to manage retinal conditions that can cause vision loss.